6887.HK
SUNSHINE PHARMA
HK$37.28
+2.14%
2026-06-01
About SUNSHINE PHARMA
Sunshine Lake Pharma Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products for the treatment of infectious diseases, chronic diseases, and oncology. It offers Kewei for the treatment of influenza; Dongweien for the treatment of hepatitis C; and generic drugs for the treatment of infections caused by sensitive bacteria, namely Clarithromycin, Levofloxacin, and Moxifloxacin Hydrochlorid, as well as active pharmaceutical ingredients. The company also engages in the wholesale, retail, import, and export of drugs. The company was formerly known as Sunshine Lake Pharma Ltd. The company was incorporated in 2001 and is based in Dongguan, China.
Key Fundamentals
P/E Ratio
57.03
EPS (TTM)
HK$0.64
ROE
6.1%
Revenue Growth (YoY)
100.2%
Profit Margin
5.7%
Debt/Equity
107.88
Price/Book
4.19
Beta
-0.10
Market Cap
HK$21.02B
Avg Volume (10D)
549K
Recent Breakout Signals
No recent breakout signals detected for 6887.HK.
Recent Price Range (60 Days)
60D High
HK$46.64
60D Low
HK$36.06
Avg Volume
324K
Latest Close
HK$37.28
Get breakout alerts for 6887.HK
Sign up for Breakout Scanner to receive daily notifications when 6887.HK triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
SUNSHINE PHARMA (6887.HK) is listed on the Hong Kong Exchanges (HKEX). Breakout Scanner monitors 6887.HK daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. 6887.HK operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry. Data is provided for informational purposes only and does not constitute financial advice.